Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference
https://finance.yahoo.com/news/dyadic-international-ceo-mark-emalfarb-133000477.html
Dyadic International, Inc.
Mon, February 7, 2022, 8:30 AM
JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company’s CEO Mark Emalfarb will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis New York City February 14th -15th, and virtually through the 17th.
Presentation Title, “Revolutionary C1 Protein Production Platform, Addressing Current Vaccine & Therapeutic Access & Affordability Using the Science of Tomorrow, Today”
Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine
https://finance.yahoo.com/news/dyadic-phibro-animal-health-announce-133000513.html
Dyadic International, Inc.
Thu, February 10, 2022, 8:30 AM
The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a targeted disease.
JUPITER, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of protein based vaccines and therapeutics, and Phibro Animal Health (“Phibro”) (NASDAQ: PAHC), a leading global diversified animal health and mineral nutrition company, jointly announced that they have entered into an exclusive license agreement for a Phibro targeted disease. This agreement follows the successful proof of concept development work, including animal trials, which was previously completed by the two companies.
Under the terms of the Agreement:
Dyadic granted Phibro an exclusive license for its proprietary C1 -cell protein production platform to produce specific targeted antigens for development and commercialization of a poultry vaccine for a Phibro targeted disease.
The parties will continue development work to find a vaccine candidate using Dyadic’s C1 cells.
The parties expect to continue working on developing additional animal vaccine candidates to be produced from Dyadic’s C1-cells.
Saw it on Yahoo: C1 outperforms everyone
Scientific article from today (20.1.22) concerning Influenza vaccine based on C1:
"Mice vaccinated with the C1-derived HA proteins elicited anti-HA immune responses similar, or stronger than mice vaccinated with HA products derived from prototypical expression systems." Cheaper, faster, better!
https://www.mdpi.com/2076-393X/10/2/148
Thank you for the laugh.
I want some C1 boneless spare ribs.
Can you imagen the C1 plantform (I mean platform) producing food in space. Call Elon Musk!
Call me when they produce a C1-based cheeseburger!
For the munchies, I mean
Great news!
Does this mean cheap plentiful THC?
Is Psilocybin next?
And Mescaline?
The potential is mind blowing!
another shot on goal, will this be highly recommended
https://finance.yahoo.com/news/dyadic-introduces-novel-method-produce-133000637.html
What's happening to the Sorrento Deal? In, Out, maybe..???? I wonder what they are proposing?
Agreed.
Contracts with payments based on milestones means the $$$$ come in only when the milestones are reched.
To me the 1/11 presentation by Mark was boring. Its not enought to present the facts. The presenter should radiate excitement about what he is talking. Otherwise how can the audiance be exxcciting about the company's potential. (Obviously just my opinion)
SHOW ME THE (MORE) MONEY!
Thanks for the post.
I assume you watched it? What is your reaction?
the DYAI platform is attractive enough to pharma that they will sign structured deals. This is non dilutive funding. I will take it.
DYAI was written up on the microcapclub.
Yahoo-live with Mark
https://finance.yahoo.com/video/really-shame-pandemic-government-didn-213303398.html
Sorrento just created a $5B shelf. That would more than do it. That started the rumor.
SRNE could not afford them
Where did you see that?
Any truth to the rumor that Sorrento is buying DYADIC?
Only a few more workdays in 2021. Wonder if Sorrento will ink the deal before the end of the year? Wonder what that deal is.
Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan
https://finance.yahoo.com/news/dyadic-announces-niimbl-coronavirus-grant-141200810.html
Under the NIIMBL grant, Dyadic will receive up to $690,000 in funding to engineer the Company’s proprietary and patented C1 thermophilic fungal (Thermothelomyces heterothallica) protein production platform to produce two different antibodies.
Research, License, and Collaboration Agreement with Janssen
https://finance.yahoo.com/news/dyai-jumpin-janssen-jamboree-092200577.html
Tue, December 21, 2021, 4:22 AM
In this article:
By John Vandermosten, CFA
NASDAQ:DYAI
READ THE DYAI RESEARCH REPORT
Research, License, and Collaboration Agreement with Janssen
On December 17, 2021, Dyadic International Inc. (NASDAQ:DYAI) released news that the company had entered into a research, license, and collaboration agreement with Janssen Biotech, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ). The agreement was facilitated by Johnson & Johnson Innovation. Details of the structure of the Janssen agreement are provided in Dyadic’s latest 8-K; however, parameter specifics, including strategic targets and payment amounts, have been redacted. According to the provided exhibit, the therapeutic proteins that Dyadic is helping Janssen to produce are likely monoclonal antibodies, which was mentioned in the addendum to the 8-K that Dyadic supplied to the SEC. The antibody target(s), however, remain undisclosed, but the partnership is a testament to the abilities for Dyadic’s C1, fungal-based technology, to produce complex therapeutic proteins.
Under the terms of the agreement:
? Dyadic will receive an upfront payment of $500,000 for non-exclusive rights to utilize the C1 platform to develop C1 production cell lines for the manufacturing of Janssen's therapeutic protein candidates against several biologic targets;
? Janssen will provide R&D funding of up to $1.8 million1 to develop and assess C1 production cell lines for its candidates;
? Janssen has option to pay mid-seven figure payment for exclusive license to use C1 for manufacturing of therapeutic proteins directed to a single, specific target;[/quote]
Think Sorrento will sign on the dotted line or walk? Never be afraid to walk away from a deal.
HC Wainwright initiates a buy recommendation with $7 price target.
I want a hat trick
many shots on goal. 1st score
https://finance.yahoo.com/news/dyadic-announces-research-license-collaboration-120000301.html
Bangladesh here we come
Patrick Lucy: https://twitter.com/PatrickKLucy
Board Member
$DYAI Pamp it
Yeap, added yesterday
Wall street shorting right into our lap
I'll pay for a dance like this everyday..
that's pretty much how i see it.
Sometimes when one breaks ranks then the others rush to follow for fear of being left behind.
No one wants to take the risk of being the first...maybe? Donno
I dont get it as well.
For 1bn the could buy a compelling technology - and not only for pharm purposes
With these obvious advantages, what keeps it from being adopted. Outside of big pharma's vested interests to protect. What is the downside of adopting and using the C1 platform?
Wow, the company anticipates stable Omicron antigen in two months after gene synthesis.
The hell with SRNE...who needs them?
If it is a Vaccine a better manufacturing process could possibly produce fewer elements that could cause undesirable reactions.
The main feature with C1 is a higher yield with less cost. Couple that with a delivery system such as the Sorrento Therapeutics SOFUSA LYMPHATIC DELIVERY SYSTEM which can lower the dose to 10% needed by an IV delivery and that can drive the retail product cost down and widen the available market considerably.
Any thoughts on how the manufacturing process impacts a drugs effectiveness?
Yes, Big ego's involved here.
Agreement isn't cancelled it was extended as Sorrento wants to enlarge it possibly to other processes and subsidiaries such as Ark Animal Health which is a wholly owned subsidiary of Sorrento.
I did not hear the fat lady sing yet.
Still in the works. Technology transfer is on going while they work on a larger deal.
There is the manufacturing of Vaccines with Dyadic technology that is being transferred to Sorrento already and a larger deal being discussed. Higher throughput in less space at lower cost with Sofusa technology opens up the gateway to servicing not only the wealthy countries but also the underserved regions of the world which is the goal of both companies and of course they want to make money while doing this; Lower cost higher volume Japanese model.
Thanks for report.
50/50 SRNE goes the distance. If it collapses we are left with nothing in the near/mid-term for incoming cash/sales. An upcoming 'collaboration' means little. Sanofi yielded nothing at the end of years of collaboration. Look out below if the SRNE deal is gone. OTOH, if SRNE moves ahead, we could easily double back to $7. A crapshoot. Mark's demeanor suggested that he believes its a crapshoot as well.
not sure that SRNE has fallen apart yet, but it is being reworked currently.
new ZACKS report
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_11112021_DYAI_Vandermosten.pdf
Nails are not in the coffin yet... May never know why it fell apart. But, it appears that SRNE CEO may be a bit of a sleazeball. Unfortunate that Mark can't attract better partners. He has a very poor record so far.
Did Mark ever say why? What was the reason for cancelling the agreement? The devil is in the detail. Over promise and under deliver?
The most encouraging part of the cc was the addition of the new hire. Otherwise, Mark seemed very tired, and seemed to have lost a step or two. I think the SRNE blow was a very significant loss, and will be challenging to properly address and overcome....assuming the deal is dead.
Followers
|
25
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1140
|
Created
|
10/19/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |